Skip to main content

Table 4 Univariate analysis of clinical variables by HIN-1/RASSF1A and RIL/CDH13panels, according to Fisher's exact test

From: Correlation between CpG methylation profiles and hormone receptor status in breast cancers

  HIN-1/RASSF1A panel RIL/CDH13 panel
  Number negative (percentage) Number positive (percentage) pvalue Number negative (percentage) Number positive (percentage) pvalue
Tumor size    0.502    0.999
1 11 (20) 8 (24)   14 (22) 5 (19)  
2 20 (36) 16 (47)   25 (39) 11 (42)  
3 12 (21) 6 (18)   13 (20) 5 (19)  
4 13 (23) 4 (12)   12 (19) 5 (19)  
Tumor grade (BNG)    0.015    0.162
1 + 2 25 (45) 25 (74)   39 (61) 11 (44)  
3 30 (55) 9 (26)   25 (39) 14 (56)  
Tumor stage    0.16    0.745
1 8 (14) 7 (21)   12 (19) 3 (12)  
2 20 (36) 17 (50)   25 (39) 12 (46)  
3 28 (50) 10 (29)   27 (42) 11 (42)  
Lymph-node metastasis    0.558    0.78
PN0 24 (43) 15 (44)   26 (41) 13 (50)  
PN1 16 (29) 12 (35)   22 (34) 6 (23)  
PN2 5 (9) 4 (12)   6 (9) 3 (12)  
PN3 11 (20) 3 (9)   10 (16) 4 (15)  
Lymphatic invasion    0.244    0.805
1 25 (52) 20 (67)   32 (59) 13 (54)  
2 23 (48) 10 (33)   22 (41) 11 (46)  
Vascular invasion    0.346    0.623
1 26 (54) 20 (67)   33 (61) 13 (54)  
2 22 (46) 10 (33)   21 (39) 11 (46)  
ER status    < 0.001    0.001
Positive 22 (42) 30 (88)   44 (72) 8 (31)  
Negative 31 (58) 4 (12)   17 (28) 18 (69)  
PR status    < 0.001    0.033
Positive 16 (30) 24 (71)   33 (54) 7 (27)  
Negative 37 (70) 10 (29)   28 (46) 19 (73)  
HR status    < 0.001    0.001
Positive 24 (45) 31 (91)   46 (75) 9 (35)  
Negative 29 (55) 3 (9)   15 (25) 17 (65)  
HER-2/neu status    0.041    0.999
Positive 7 (14) 0 (0)   5 (9) 2 (8)  
Negative 43 (86) 30 (100)   50 (91) 23 (92)  
Triple-negative    0.001    < 0.001
No 33 (59) 31 (91)   53 (83) 11 (42)  
Yes 23 (41) 3 (9)   11 (17) 15 (58)  
  1. BNG, Black's nuclear grade; ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor.